AtriCure (ATRC) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance

AtriCure (NASDAQ: ATRC) reported Q2 EPS of $0.18, $0.19 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $153.6 million versus the consensus estimate of $151.84 million.

GUIDANCE:

AtriCure sees FY2026 EPS of $0.24-$0.32, versus the consensus of $0.12.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Stripe, Advent In Talks To Buy Paypal - WSJ